Transcript Slide 1
Distributed Specialty Care a telemedicine model for delivery of dermatology specialty care in VISN 2 Craig C. Miller, MD, PhD Brian C. Madden, PhD 13 November 2006 Overview Why? Imbalance between supply of dermatology specialists and demand for treatment of skin diseases in VISN 2 How? Distributed Specialty Care model • Three-tiered system for delivery of skin care • Primary care provider • Skin Evaluation Clinic • Teledermatology consultant Shortage of dermatology assets in VISN 2 Dermatology demand Over 12,000 patient visits per year Requirement to provide veterans with “specialty care” Time constraints: 30-30-20 rule Dermatology supply Limited VA staff dermatologists • Disconnect between VA and civilian sectors • Non-priority Lack of acceptable non-VA care • Limited availability--unacceptable delays • Expensive VISN2 Dermatology Assets DSC model: goals Allows for more efficient utilization of dermatology specialty assets Maintains high quality of care for skin related disease • Timely • Efficacious DSC model: key features Store-forward technology Skin Evaluation Clinic Trained non-specialist skin care providers Intermediaries between primary care and the specialist Performance measures Dynamic adaptive system Continuous enhancement Telemedicine methodology Real-time Video with synchronous (“face-to-face”) patientconsultant encounters • Low resolution, high bandwidth • Inefficient utilization of consultant Store-forward Still images with asynchronous patient-consultant encounters • High resolution, low bandwidth • Efficient utilization of consultant • Dependent upon skills of non-specialist • Obtain proper history • Decide on what is “image worthy” • Self-initiate therapeutics and/or diagnostic procedures DSC: Three-tier delivery system Primary Care Provider Service Agreement Skin Evaluation Clinic Rules of Engagement Teledermatology Consultant Tier 1: Primary care provider Identify patient with skin complaint Utilize Skin Evaluation consult menu to direct patient care Initiate consultation with Skin Evaluation Clinic (when appropriate) Skin Evaluation consult menu Decision Tree for managing patients with skin dz Service Agreement Determines appropriateness of consultation Directs patient flow Directs initial therapeutic approach for established skin diseases Prioritizes unknown skin conditions Suggests alternative approaches for skin disorders that are not referable to SEC Skin Evaluation consult request form Asks for reason for consult and whether patient has been seen previously in SEC Dermatology Decision Tree: an algorithm for skin dz patient flow Disease Decision Tree for Dermatology P atient with Skin Problem P resents t o P CP Q1: Is it emergent? N Y Send t o ED Q2: Is it a known Dx? Y N Q3: Is it appropriat e for dermatology? Send t o Skin Evaluation N Y Send t o Other Service / Off Service Q4: Is it treatable? Y N Send t o Skin Evaluation Q5: Is it responsive? N Send t o Skin Evaluation Y Discharge or maintenance (patient remains with P CP ) Components of Service Agreement Part A Part B Known conditions and treatments Priorities of unknowns and areas of concern Part C Uncovered items (limited resources) APPEND IX 1: PCP/SEC Se rvice Agre e me nt Ğ Protocol for Sche dulingConsults Will accept referrals to the teledermatology service for some known conditions of the skin that have failed treatment attempts (see part A) and conditions of the skin with uncertain diagnoses (see part B) but w ill not accept referral s for som e otherskin conditions (see part C). (A) Will accept referrals for the following known conditions Treatment needed prior to consultation: only after initialtherapy has fai led: Psoriasis Trunk/extremi ties: fluocinonide ointment qhs and calcipotriene ointment qam for 8 weeks. Body fol ds: cal cipotriene oi ntment and desonide ointment +/ketoconazole cream bid for 8 weeks. Seborrheic dermatitis Scalp: cal cipotriene scalp solution qam, betamethsone valerate foam qhs for 8 weeks. Scalp: ketoconazole shampoo 2-3 times a week; beta methsone valerate foam qhs prn itching for 6-8 weeks. Face/ears/chest: ketoconazole and desonide creams bid for 6-8 weeks. Rosacea Stasi s dermatitis Hand eczema Dermatophyte infection (tinea cruris, tinea pedis, tinea corpori s, tinea manum) Acne Acute (< 6 wks) urticaria (Òhi vesÓ) Ini tiall y trymetronidazole cream bidto face for 6-8 weeks; if no improvement, try clindamycin 1% solution or sulfacetamide/sulfur lotion bid or, for more severe cases, tetracycline 500 mg PO bidfor 8 weeks. Leg elevation, compressi on stockings (20 mm Hg/below the knee-make sure there is no lower extremi ty arterial disease), and triamcinolone 0.1% ointment qhs for 6-8 weeks; if ulcers are present, try silvadene cream; if no improvement, refer to Vascular/Wound Care Clinic. Clobetasol ointment bid for 4 weeks. Tell patient to avoid irritants (e.g. frequent hand washing/chemicals/detergents). Loprox bid for 6-8 weeks. For mild acne, use a topical anti bioticsuch as clindamycin solution qam and a topic al retinoid such as tretinoin 0.025% cream qhs for 6-8 weeks. For more severe inflam matory acne, use the above topicals in addition to an 8 week course of an oral anti bioti c such as tetracycline 500 m g PO bid,doxycycline 100 m g PO bid, or minocycline 100 m g PO bid. Oral antihistamines; consider prednisone taper (starting with 40-60 mg qam and tapering over 2 wks); identifyand mit igate underly ing eti ology (e.g., drugs, infection, foods) Warts (non-genital) Genital warts (m ale) (B) Will accept referrals for unknown conditions with the fol lowing signs or symptom s: Ini tiall y tr eat with topic al sali cylic acid plaster for 8 weeks and/or liquid nitrogen for 3 treatments, 4 weeks apart. Podophyllin solution M-W-F for 4 wks, cryotherapy (li quid nitrogen) or imiquimod cream M-W-F for 4 wks. Details: SEC appointment priority: Blistering | purpuric < 10% BSA and non-syst em i c Blistering | purpuric > 10% BSA or system i c Other Any +ABCD | ulcerated Other Ulcerated | m ultinodular | rapid growth (< month) Other Pruritus / Dysesthesia Deep derm al orsub-cutaneous nodules with no overlying change Maski ng of signs by dark skin tones (Types V-VI) w/i 24-48 hours (C) Will not accept referrals for: Suggesti ons: Consider referral to: Rem oval of skin tags Lim i ted liquid nitrogen (try Òfr eeze clampÓtechnique - dip needle holder in liquid nitrogen and then pinch skin tags until rozen f down to the base). Consider no treatment given the cost, potenti alside effects of oral therapy, and high rate of recurrence. No treatment is necessary unless clinically indicated. Liquid nitrogen (requires less than what a wart requires). SURGERY/ENT /OPHT HO Acute Rash Chronic Rash Pigmented Lesion Non-Pigmented Lesion No visible signs Toenail onych om ycosis (fungal nail ) Rem oval of benign melanocyticnevi (ÒmolesÓ) Rem oval of seborrheic keratoses (we will treat an irri tated/i nfl amed lesion that is causing the patient discomfort; please do not refer patients for purely cosm eti c reasons) Treatment of genital warts T ry podophyllin soluti on,liquid (fem ale) nitrogen, or imiquimod cream . Topical medication renewal Refer to Derm atology Note for any restrictions on use send to ED prom ptly w/i w/i w/i w/i w/i 1 week 4 weeks 1 week 4 weeks 2 weeks w/i 4 weeks w/i 4 weeks w/i 4 weeks w/i 4 weeks PODIATRY SURGERY or ENT SURGERY or ENT OB-GYN N/A Tier 2: Skin Evaluation Clinic Evaluate patient Initiate treatment or perform diagnostic tests Acquire images according to the “rules of engagement” Enter teledermatology consult (when appropriate) Skin evaluation clinic providers Various backgrounds Nurse practitioners/Physician assistants Dermatology residents Primary care physicians Training Training in dermatology clinic • Approach to the dermatology patient • Rudimentary dermatology differential diagnosis • Introduction to dermatology therapeutics Hands-on training in techniques • Biopsy--shave, punch • Cryotherapy • Electrodessication and curettage Hands-on training in image acquisition Access to dermatology educational resources Feedback Rules of Engagement Initial consult that specifically refers to evaluation of a lesion for suspected malignancy Any patient in which there is a question as to the diagnosis that may affect treatment approach such that the consequence of proceeding along one of alternative lines of therapy could result in a delay in appropriate and prognostically significant care Any patient that requires a biopsy Any patient that will be started on systemic medications that require monitoring Patch test evaluation The Camera 8 MP SLR camera Macro lens Macro flash Back-up available Technical support The Canon EOS Digital Rebel with the Canon EF 100mm f/2.8 USM Macro Lens and Canon Macro Twin Lite Image acquisition/capture Image acquisition Patient ID Contextual (anatomic context) Morphological (diagnostic close-up) Image capture Client software/access Card reader Image quality Literature Standards for image resolution/color supports the validity of teledermatology in diagnosis of skin lesions DSC standards >> American Academy of Dermatology and the American Telemedicine Association Future DICOM standard Techniques to ensure image quality Standard and simple image acquisition process Calibration for “true” colors Training Feedback Validation Tier 3: Teledermatology consultant Review SEC note View images VistA Image Display Document Emphasis on history Link to Teledermatology consultation Template Code DSC: Three-tier delivery system Primary Care Provider Service Agreement Skin Evaluation Clinic Rules of Engagement Teledermatology Consultant Performance Training Basic dermatology therapeutics/procedures Image acquisition Resources • Reference materials • Continuing education Validation Diagnostic accuracy • JCAHO requirement Business plan • Cost effective • Healthcare product of sufficient quality • Patient satisfaction • Morbidity/mortality statistics DSC: Strategy for success Personnel Performance Process Primary care provider (PCP) Skin evaluation clinic non-specialist provider Teledermatology consultant VISN2 Telemedicine consultant Patient management via CPRS Image acquisition Store-forward teledermatology Coding Performance Training Resources Validation Personnel Process VISN2 Teledermatology Initiative